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What blood tests help diagnose
celiac disease?
z Evidence summary
Celiac disease (also called celiac sprue,
nontropical sprue, or gluten-sensitive
enteropathy) is an autoimmune disorder
classified by intestinal inflammation and
malabsorption in response to dietary
gluten—a storage protein component of
wheat gliadins. Celiac disease patients—
0.5% to 1.0% of the US population1—are
often sensitive to other closely related grain
proteins found in oats, barley, and rye.
Celiac disease’s classic histological
finding is an infiltrative small intestine
lesion characterized by villous flattening,
crypt hyperplasia, and lymphocyte accu-
mulation in the lamina propria.2 The
American Gastroenterological Associa-
tion’s (AGA) diagnostic criteria include
Histological confirmation of infiltrative
lesions via small bowel biopsy is the gold
standard for diagnosing celiac disease.
Four serum antibody assays may serve as a
first-step diagnostic tool to identify biopsy
candidates: immunoglobulin A tissue 
transglutaminase (IgA tTG), IgA endomysial
antibody (IgA EMA), IgA antigliadin antibody
(IgA AGA), and IgG antigliadin antibody (IgG
AGA). IgA tTG and IgA EMA offer the best
diagnostic accuracy. Patients with selective
IgA deficiency may have falsely negative 
IgA assays (strength of recommendation
[SOR]: B, based on a systematic review,
multiple small cross-sectional studies, and
expert opinion).
E V I D E N C E - B A S E D A N SW E R
The most reliable testing option 
is also the most cost-effective
When faced with a cryptic array of available
serologic tests for celiac disease, and often
pressed for time to look up which one is
best, we are often quite tempted to simply
check “Celiac Panel” on the lab order sheet
and just order them all. However, the
authors present us with an evidence-based
rationale for limiting our lab testing to just
one of the available serologic tests.
What a delight to find that the most 
reliable testing option is also the most 
cost-effective. At our university hospital, the 
billable cost of each serologic marker for
celiac disease is approximately $50, and the
entire panel—which includes IgA tTG, IgG
tTG, IgA EMA, and IgA/G AGA—is $250.
Rather than ordering the redundant panel
(why include anti-AGA at all?), it is far better
to start with IgA tTG or IgA EMA, and 
follow-up with IgG levels if necessary.
When ordering these tests, it is worth 
noting that some physicians recommend
patients be on a gluten-containing diet for 
2 to 4 weeks before serologic testing, to
minimize the possibility of insufficient 
antibody titers.
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confirmation of this abnormal mucosa and
unequivocal improvement on repeat biop-
sy following a gluten-free diet.3 However,
either clinical improvement or biopsy of
dermatitis herpetiformis skin lesions (com-
mon occurrences in celiac disease) are
often considered adequate for diagnosis
without repeat intestinal biopsies.
Its reversible nature makes prompt
diagnosis of celiac disease important.
Three antibodies commonly appear in celi-
ac disease patients: antibodies to tTG, anti-
endomysial antibodies, and antigliadin
antibodies.4–6 AGA binds dietary gluten
and EMA binds the enzyme tTG, which is
found in connective tissue surrounding the
smooth muscle cells in the intestinal wall.
The gluten-autoantibody interaction
in the small intestinal lumen has IgA as its
major component; IgG represents a longer-
term immune response. Serum assays of
the IgA and IgG forms of AGA and tTG
are enzyme-linked immunosorbent assays
(ELISA); EMA is measured by indirect
immunofluorescence.5,6
In 2 studies of the diagnostic accuracy
of IgA tTG, 95% to 98% of biopsy-proven
celiac disease patients had positive tests,
while only 5% to 6% of controls were 
positive.4,5 In a systematic review, there was
no statistically significant difference
between IgA EMA and IgA tTG—both
had sensitivities greater than 90% and
specificities greater than 95%.7 IgA AGA
did not perform as well (sensitivity
80%–90%, specificity 85%–95%). The
TABLE summarizes the diagnostic accuracy
of the various tests.
Two to 3% of patients with celiac dis-
ease have selective IgA deficiency.2 These
patients often have falsely negative serum
IgA assays (for EMA, tTG, and AGA), so
IgG is a diagnostic alternative.8,9 In a cross-
sectional study, 100% of 20 untreated celi-
ac disease patients with IgA deficiency had
positive IgG tests for tTG, AGA, and EMA
despite negative IgA tests for the same anti-
bodies.9 Eleven patients with celiac disease
and no IgA deficiency all had positive tTG,
AGA, and EMA tests, whether testing for
the IgA or IgG forms.
Despite the performance of the IgG
assays in this study, only IgG AGA has per-
formed well in larger studies. In a system-
atic review, IgG tTG and IgG EMA had
specificities of 95% but sensitivities of only
40%.7 IgG AGA has similar sensitivity to
the IgA assay—approximately 80%—with
a slightly lower specificity of 80%. The
discrepancy in the sensitivity of IgG tTG
and IgG EMA between studies occurs
because of differing antibody levels with
variations in dietary gluten.9,10 Therefore,
testing for IgG tTG and IgG EMA should
be reserved for patients with selective IgA
deficiency.
Another notable limitation of using
serologic markers to diagnose celiac dis-
ease is poor sensitivity in patients with
mild disease.11 Diagnosis in these patients
may be particularly challenging. Patients
with karyotype abnormalities and those
with diabetes are also more likely to have
false-negative serologic tests.2
Recommendations from others
The AGA recommends using serologic
markers to screen patients with either non-
specific symptoms or medical conditions
that increase the risk of celiac disease.3
Rather than 
ordering a 
redundant panel,
it is far better to
start with IgA tTg
or IgA EMA,
and follow up 
as necessary
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Diagnostic accuracy of serologic tests 
for celiac disease patients with normal IgA levels
SEROLOGIC TEST SN SP LR+ LR–
IgA tTG 95%–98% 94%–95%
.95 .94 16 0.05
IgA EMA >90% >95%
.91 .96 23 0.09
IgA AGA 80%–90% 85%–95%
.85 .90 8.5 0.17
IgG tTG 40% 95% 8 0.63
IgG EMA 40% 95% 8 0.63
IgG AGA 80% 80% 4 0.25
Sn, sensitivity; Sp, specificity; LR+, likelihood ratio of a positive test result; 
LR–, likelihood ratio of a negative test result.
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Patients whose clinical profile causes a
high index of suspicion and negative IgA
serologic markers should be tested for
selective IgA deficiency. The AGA recom-
mends relying on small intestinal biopsy
for the final diagnosis. 
Both the AGA and the North
American Pediatric Society for Pediatric
Gastroenterology state that tissue transglu-
taminase and endomysial antibodies are
the most useful serologic tests. Antigliadin
antibody tests are considered inferior in
terms of diagnostic accuracy. n
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